SciELO - Scientific Electronic Library Online

 
vol.83 número2Excreción de SARS-CoV-2 infeccioso en dos niños asin tomáticos índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Medicina (Buenos Aires)

versão impressa ISSN 0025-7680versão On-line ISSN 1669-9106

Resumo

DAMILANO, Roxana A.  e  BERGOGLIO, Marina T.. Adrenocortical carcinoma in women of reproductive age. Medicina (B. Aires) [online]. 2023, vol.83, n.2, pp.307-. ISSN 0025-7680.

Adrenocortical carcinomas are rare tumors, usually hyperfunctioning, with poor overall survival. Frequent age of presentation is described in adults between 40 and 60 years of age, predominantly female. Two unusual cases of adrenal carcinoma diagnosed in young women are presented. The first one was discovered in the sec ond trimester of gestation, with signs and symptoms of hypercortisolism and localized adrenal lesion, which was resolved with complete resection by week 20 of pregnancy. In the second case, the patient begined with clinical manifestations of rapidly progressive virilization, the biochemical pattern being pure hyperandrogenism. In both cases, despite complete resection, the high Ki67 as the main prognostic factor leaded to categorization as “high risk of recurrence”. In addition, pregnancy and glucocorticoid secretory pattern have been associated as additional risk factors of recurrence. This is particularly high within the first two years after diagnosis. There is controversy about the use of adjuvant mitotane in these patients, and the general recommendation is to be started no longer than 3 months after surgery. However, the available evidence does not suggest that its use is ineffective beyond that period. Limitations, such as the course of pregnancy and the immediate puerperium, as well as the difficulty of accessing this medication in our environment, prevented the early initiation of adjuvant treatment with mitotane in both cases, although there is still concern whether its administration would still be appropriate.

Palavras-chave : Adrenal carcinoma; Cushing syndrome; Gestation; Mitotane.

        · resumo em Espanhol     · texto em Espanhol